Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter

Urology

Volumn 60, Issue 4 SUPPL., 2002, Pages 31-35

  Horninger, Wolfgang ^a   Cheli, Carol D ^b   Babaian, Richard J ^c   Fritsche, Herbert A ^c   Lepor, Herbert ^d   Taneja, Samir S ^d   Childs, Stacy ^e   Stamey, Thomas A ^f   Sokoll, Lori J ^g   Chan, Daniel W ^g   Brawer, Michael K ^g   Partin, Alan W ^h   Bartsch, Georg ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b BAYER CORPORATION   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e Wyoming Research Foundation   (United States)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^g DEPARTMENT OF PATHOLOGY   (United States)

^h Northwest Prostate Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER TISSUE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0036789920     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01693-X     Document Type: Article

References (21)

1. Greenlee R.G., Murray T., Bolden S., et al. Cancer statistics 2000. CA Cancer J Clin. 50:2000;7-33.
2. Gee W.F., Holtgrewe L., Albertsen P.C., et al. Practice trends in the diagnosis and management of prostate cancer. J Urol. 154:1995;207-208.
3. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 58:2001;417-424.
4. Bostwick D.G. Prostate-specific antigen current role in diagnostic pathology of prostate cancer . Am J Clin Pathol. 102:1994;31-37.
5. Horninger W., Reissigl A., Klocker H., et al. Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate. 37:1998;133-137.
6. Okihara K., Fritsche H.A., Ayala A., et al. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/ml. J Urol. 165:2001;1930-1936.
7. Horninger W., Volgger H., Rogatsch H., et al. Considerations of low PSA cutoff levels to optimize the detection of curable prostate cancer. Eur Urol. 39:2001;43-46.
8. Jung K., Stephan C., Elgeti U., et al. Molecular forms of prostate specific antigen in serum with concentrations of total prostate specific antigen <4 microg/L are they useful tools for early detection and screening of prostate cancer? Int J Cancer. 93:2001;759-765.
9. Oesterling J.E. Prostate-specific antigen a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate . J Urol. 145:1991;907-923.
10. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men . J Urol. 151:1994;1283-1290.
11. Stenman U.H., Leinonen J., Alfthan H., et al. A complex between prostate specific antigen and alpha1-symotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer assay of the complex improves clinical sensitivity for cancer . Cancer Res. 51:1991;222-226.
12. Lilja H., Christensson A., Dahlen U., et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
13. Lilja H., Cockett A.T.K., Abrahamsson P.-A. Prostate specific antigen predominantly forms a complex with alpha1-antichoymotrypsin in blood. Cancer. 70:1992;230-234.
14. Espana F., Martinez M., Sanchez-Cuenca J., et al. Prostate specific antigen and its complexes with alpha-1-antichymotrypsin in the plasma of patients with prostatic disease. Eur Urol. 30:1996;512-528.
15. Jung K., Brux B., Lein M., et al. Determination of alpha1- antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. Urology. 53:1999;1160-1168.
16. Brawer M., Mayer G.E., Letran J.L., et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology. 52:1998;372-378.
17. Brawer M., Cheli C.D., Neaman I.E., et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol. 163:2000;1476-1489.
18. Okegawa T., Noda H., Nutahara K., et al. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer. Eur Urol. 38:2000;380-387.
19. Wilson J.M., Jungner Y.G. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 65:1968;281-393.
20. Jung K., Lein M., Brux B., et al. Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions. Clin Chem Lab Med. 38:2000;1271-1275.
21. Piironen T., Pettersson K., Suonpaa M., et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology. 48:1996;81-87.